Intracoronary administration of abciximab acutely increases flow through culprit vessels of patients with acute coronary syndromes undergoing percutaneous coronary intervention.
暂无分享,去创建一个
[1] V. Hombach,et al. Reduction of Major Adverse Cardiac Events With Intracoronary Compared With Intravenous Bolus Application of Abciximab in Patients With Acute Myocardial Infarction or Unstable Angina Undergoing Coronary Angioplasty , 2003, Circulation.
[2] C. Bode,et al. Abciximab, Eptifibatide, and Tirofiban Exhibit Dose-dependent Potencies to Dissolve Platelet Aggregates , 2003, Journal of cardiovascular pharmacology.
[3] R. Jordan,et al. An Additional Mechanism of Action of Abciximab: Dispersal of Newly Formed Platelet Aggregates , 2002, Thrombosis and Haemostasis.
[4] J. Soria,et al. Disaggregation of In Vitro Preformed Platelet-Rich Clots by Abciximab Increases Fibrin Exposure and Promotes Fibrinolysis , 2001, Arteriosclerosis, thrombosis, and vascular biology.
[5] E. Braunwald,et al. TIMI frame count: a quantitative method of assessing coronary artery flow. , 1996, Circulation.